Abstract
Objective:
To report a case of a man who developed temporary hypotension after aerosolized colistin administration.
Case Summary:
A 62-year-old Arab male was admitted to the intensive care unit for respiratory failure and septic shock. Simultaneous therapy using intravenous and aerosolized colistin was initiated for the management of multidrug-resistant Pseudomonas aeruginosa. A significant but transient drop in blood pressure occurred when aerosolized colistin was introduced. However, when it was stopped, but intravenous administration was continued, no hypotension was observed. Moreover, the combined use of aerosolized amikacin with intravenous colistin did not significantly affect blood pressure.
Discussion:
It is widely accepted that aerosolization allows safe administration of colistin in the absence of significant systemic adverse effects. However, in our patient, hypotension was observed with aerosolized colistin, but not with the systemic formulation. The lack of adverse effects with administration of aerosolized amikacin in this patient demonstrates the safety of the aerosolization technique. Use of the Naranjo scale indicated a probable relationship between hypotension and aerosolized colistin administration.
Conclusions:
This case suggests that hypotension may be induced with administration of aerosolized colistin. Although this effect is rare, clinicians should be aware that hypotension may develop in critically ill patients following aerosolized colistin treatment.
Get full access to this article
View all access options for this article.